Cytokinetics Inc at JPMorgan Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Tessa Romero - J.P. Morgan - Analyst : So Robert, you just talked about your key priorities and the targets you're looking to achieve in 2025 and longer term as well. Can you talk a little bit about your strategy around resource allocation? And how do you think about investing behind aficamten and its launch and also your broadening pipeline?

Question: Tessa Romero - J.P. Morgan - Analyst : So as we think about aficamten, what do you think you need to succeed on in order to have a strong launch here out of the gate and also longer term?

Question: Tessa Romero - J.P. Morgan - Analyst : Okay. And along the same lines, can you talk a little bit about how you arrived at over 100,000 patients globally, hopefully on your medicines in your 2030 vision?

Question: Tessa Romero - J.P. Morgan - Analyst : Can you orient us to where you stand in your regulatory processes in both the US and Europe?

Question: Tessa Romero - J.P. Morgan - Analyst : Can you talk a little bit about who you've been interacting with at the FDA?

Question: Tessa Romero - J.P. Morgan - Analyst : Is it the same team that was involved with omecamtiv?

Question: Tessa Romero - J.P. Morgan - Analyst : Do you think the FDA needs to see data with the updated FOREST-HCM protocol before approval of aficamten, given those insights could potentially guide a potential REMS strategy? And maybe you could recap the key events that led to the adjusted protocol for anyone that might not be familiar?

Question: Tessa Romero - J.P. Morgan - Analyst : Given the overall profile of aficamten, the strength of your data, its pharmacology, how might this lend itself to a differentiated growth curve versus [camzyos]? And maybe what have you learned from others in terms of any potential challenges to anticipate as you launch the drug?

Question: Tessa Romero - J.P. Morgan - Analyst : Last question from me. Where are you most excited in your broader pipeline? And what do you think might be more overlooked by investors? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 13, 2025 / 5:00PM, CYTK.OQ - Cytokinetics Inc at JPMorgan Healthcare Conference